Acquiring Company
VistaGen
Acquired Company
Pherin
South San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaTherapeuticsPharmaceuticalDescription
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Pherin Pharmaceuticals, Inc., a clinical-stage drug development company focused on the discovery and development of investigational pherine compounds for treatment of neuropsychiatric and neuroendocrine conditions (Pherin), today announced that the companies have entered into a definitive agreement under which Vistagen will acquire Pherin for approximately 12.4 million shares of Vistagen common stock and a nominal amount of cash.
Quick answer
VistaGen is acquiring Pherin, announced December 21, 2022. VistaGen is based in South San Francisco, California, United States.
- How much did VistaGen pay for Pherin?
- The deal value was not disclosed.
- What does VistaGen do?
- Vistagen is a late clinical-stage biopharmaceutical company headquartered in South San Francisco, CA, developing and commercializing a new class of intranasal product candidates called pherines.
- Where are VistaGen and Pherin based?
- VistaGen is based in South San Francisco, California, United States.
- Who are the decision-makers at VistaGen?
- Fundz holds 1 contact at VistaGen. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Vistagen Announces Closing Of Pherin Pharmaceuticals Acquisition (February 2, 2023)
- Merck Completes Tender Offer To Acquire Imago Biosciences, Inc. (January 11, 2023)
- Solid Biosciences Announces Closing Of Acquisition Of Aavantibio And Concurrent $75 Million Private Placement, $75M (December 5, 2022)
- Rocket Pharmaceuticals Completes Acquisition Of Renovacor (December 1, 2022)
- Solid Biosciences Announces Stockholder Approval Of Acquisition Of Aavantibio (December 1, 2022)
- Lilly Completes Acquisition Of Akouos Expanding Efforts To Help People With Genetic Diseases (December 1, 2022)
Who to call at VistaGen, and when
When VistaGen changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day VistaGen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at VistaGen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at VistaGen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment VistaGen makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Pherin?
Pherin was acquired by VistaGen, based in South San Francisco. The deal was reported on December 21, 2022. Vistagen is a late clinical-stage biopharmaceutical company headquartered in South San Francisco, CA, developing and commercializing a new class of intranasal product candidates called pherines. VistaGen is publicly traded (VTGN) and operates in Biotechnology.
When did VistaGen acquire Pherin?
VistaGen's acquisition of Pherin was reported on December 21, 2022. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Pherin do?
Pherin Pharmaceuticals is a privately held company focused on the discovery and development of pherines for acute, intermittent, and long-term treatment of a broad range of human diseases and disorders. It is privately held, operating in Therapeutics.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.